Company profile: Graviton
1.1 - Company Overview
Company description
- Provider of clinical-stage biotech therapies, developing selective ROCK2 inhibitors for fibrotic, autoimmune and CNS diseases; a C6 monoclonal antibody for neurodegenerative diseases; and DYRK inhibitors for diabetes, neurological disorders and cancers. Conducts clinical trials and partners with Ovid Therapeutics and Sino Biopharmaceutical for development and commercialization.
Products and services
- C6 Monoclonal Antibody: Graviton Bioscience architects a targeted monoclonal antibody against C6 to treat neurodegenerative diseases by controlling activity of complement system component C6
- DYRK Inhibitors: Graviton Bioscience engineers family-specific inhibitors of the DYRK protein kinase family, recalibrating kinase activity to address diseases like diabetes, neurological disorders, and cancers
- ROCK2 Inhibitors: Graviton Bioscience develops selective ROCK2 inhibitors that modulate the Rho signaling pathway to treat fibrotic, autoimmune, and CNS diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Graviton
Galapagos
HQ: Belgium
Website
- Description: Provider of small molecule medicines and investigational therapies in immunology and oncology. Develops CAR-T cell therapies via a decentralized manufacturing network and advances GLPG5101 (Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma). Conducts clinical trials to evaluate treatments and seek regulatory approval; Jyseleca (filgotinib) transferred to Alfasigma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galapagos company profile →
Alvine Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for autoimmune and gastrointestinal diseases; developing and commercializing treatments including ALV003, a combination protease engineered to digest gluten for patients with celiac disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alvine Pharmaceuticals company profile →
Serimmune
HQ: United States
Website
- Description: Provider of antibody repertoire profiling and immune analytics via the Serum Epitope Repertoire Analysis (SERA) platform to identify disease-specific antigens and epitopes in a single assay; immune profiling with high-resolution epitope mapping and immune status reports; biomarker discovery across infectious diseases, cancer, and autoimmunity; Titan panel covering 50+ infectious diseases; and population serosurveillance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Serimmune company profile →
Forward Pharma
HQ: Denmark
Website
- Description: Provider of biotechnology focused on the immunomodulatory compound dimethyl fumarate and derivatives for pharmaceutical drug applications to treat immune disorders such as multiple sclerosis and psoriasis; founded in 2005 and headquartered in Copenhagen, Denmark.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forward Pharma company profile →
Mount Tam Biotech
HQ: United States
Website
- Description: Provider of services to develop, optimize, and bring to market novel pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mount Tam Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Graviton
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Graviton
2.2 - Growth funds investing in similar companies to Graviton
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Graviton
4.2 - Public trading comparable groups for Graviton
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →